300P - Predictive factors for nonsentinel lymph node metastasis in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Breast Cancer, Metastatic
Presenter Jai Min Ryu
Citation Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365
Authors J.M. Ryu, S.J. Nam, J.E. Lee, J. Yu, S.K. Lee, S.Y. Bae, H. Paik, S. Park
  • Surgery, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR

Abstract

Background

Axillary lymph node (ALN) status is an important prognostic factor for breast cancer patients. With increasing numbers of patients undergoing neoadjuvant chemotherapy (NAC), issues concerning sentinel lymph node biopsy (SLNB) after NAC have emerged. We analyzed clinicopathological features and developed a nomogram to predict the possibility of nonsentinel lymph node (NSLN) metastases in patients with positive SLNs after NAC.

Methods

A retrospective chart review was performed for 141 patients who were clinically ALN positive at presentation, had a positive SLN after NAC on subsequent SLNB, and underwent axillary lymph node dissection (ALND) between 2008 and 2014.

Results

On univariate analysis, SLN metastasis size, clinical ALN status after NAC, lymphovascular invasion (LVI), number of positive SLNs, number of negative SLNs, and pathologic T stage were significantly associated with likelihood of NSLN metastases (P 

Conclusions

The NAC nomogram was developed to predict the likelihood of additional positive NSLNs because this information may help dictate appropriate axillary surgery in the future as we strive to safely minimize axillary morbidity.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea. (HI14C3418)

Disclosure

All authors have declared no conflicts of interest.